RE:RE:RE:RE:RE:RE:This gives me less and less and less confidenceAngelaL wrote: Salzman has published in world-class publications if you took the time to read the list. Journals like PNAS, Circulation Research, Journal of Inmunology, Gastroebterokogy, etc. From the bio on the website of his company it's clear he left academia in 1999 so that it is not at all surprising that he didn't publish mich after that. He was the first to develop PARP inhibitors for humans, a drug class which is now a mainstay in treatment of breast and ovarian cancer. Look at his partnering deal with Genentech, the world's top cancer company, which licensed his invention (see link below). You'd be way off base not to regard this guy as world class. By the way, have you done 1% of what he's accomplished?
https://www.pharmaceuticalonline.com/doc/genentech-inc-inotek-pharmaceuticals-corporat-0001
so a couple things on this; saying that he was first to develop PARP inhibitors seems to be a wild stretch. his co-contributed paper is referenced along with a few hundred other references on Nature.com article
The role of PARP in DNA repair and its therapeutic exploitation: https://www.nature.com/articles/bjc2011382.pdf?origin=ppub click control+F Salz to try and find him
There is very little that references his contribution to PARP; google ADP-Ribose and most of it circles back to pubmed journals on pubmed.
it DOES NOT show up in examples of clinical trials for PARP inhibitors:
https://en.wikipedia.org/wiki/PARP_inhibitor#Examples_in_clinical_trials
he does have a very small reference in the wiki of Poly ADP-ribose, but again nothing that seems to be a mainstay of any sort
https://en.wikipedia.org/wiki/Poly_(ADP-ribose)_polymerase#Functions
INOTEK's wiki doesnt really state much considering your claims regarding breast and ovarian cancer. they SEEM to be still active, and had an IPO in 2015, but no great contributions related to Salzmans work
https://en.wikipedia.org/wiki/Inotek_Pharmaceuticals
Genentech's wiki is much more robust, but then again this is a company not founded by Salzman. looking at there wiki's product timeline there is ZERO reference to anything related to the inotek licencing agreement in 2006, or anything related to ribrose, PARP or inotek. the closest thing was this statement
https://en.wikipedia.org/wiki/Genentech#Products_timeline:
"It was most publicized for its approval in advanced breast cancer treatment, but the FDA approval for breast cancer treatment was subsequently revoked in November 2011."
I am merely doing the due diligence I should have done prior to investing in this company, they seemed to have jumped from one buzz word to the next (cancer, canniboids, and now covid)
there is no need for you to devolve the conversation into personal attacks over DD, I am 100% open to counter DD